First-in-human study of CPL’116 – a dual JAK/ROCK inhibitor – in healthy subjects

First-in-human study of CPL’116 – a dual JAK/ROCK inhibitor – in healthy subjects

BackgroundCPL’116 is a novel Janus kinase (JAK) and Rho-associated coiled-coil containing protein kinase (ROCK) dual inhibitor and a promising drug candidate for the treatment of inflammatory and fibrotic diseases. We conducted this first-in-human, Phase I clinical trial to evaluate the safety, phar...

Full description

Saved in:
Bibliographic Details
Main Authors: Piotr J. Rudzki, Katarzyna Jarus-Dziedzic, Dorota Włodarczyk, Michał Kaza, Piotr Pankiewicz, Agnieszka Gierczak-Pachulska, Martyna Banach, Beata Zygmunt, Cezary Piwowarczyk, Paweł Żero, Daniel Rabczenko, Agnieszka Segiet-Święcicka, Maciej Wieczorek
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Pharmacology
Subjects:
phase I (drug development)
safety
pharmacokinetics
pharmacodynamics
CPL’116 (previously CPL409116)
Janus kinase (JAK)
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1583723/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1583723/full

Similar Items